Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative RNA-based therapies for severe genetic diseases. Founded in 2018, Stoke has quickly established itself in the biopharmaceutical industry, particularly in the field of genetic medicine. The company is renowned for its proprietary TANGO™ platform, which uniquely enhances the expression of specific genes to address the underlying causes of diseases. This cutting-edge approach sets Stoke apart in a competitive market, positioning it as a leader in the development of treatments for conditions such as epilepsy and other neurological disorders. With a commitment to advancing genetic therapies, Stoke Therapeutics continues to achieve significant milestones, solidifying its reputation as a key player in the biotechnology landscape.
DitchCarbon Score
How does Stoke Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Stoke Therapeutics, Inc.'s score of 20 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Stoke Therapeutics, Inc.'s reported carbon emissions
Stoke Therapeutics, Inc., headquartered in the United States, has set ambitious climate commitments despite not having specific carbon emissions data available for recent years. The company has established near-term targets to reduce its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by approximately 42% by 2030, using 2023 as the base year. Furthermore, Stoke aims for a significant long-term reduction, committing to a 90% decrease in Scope 1, Scope 2, and Scope 3 emissions by 2050. In addition to these reduction targets, Stoke Therapeutics has pledged to achieve net-zero emissions by 2050. This commitment aligns with the Science Based Targets initiative (SBTi) and is designed to support global efforts to limit warming to 1.5°C. The company’s proactive approach reflects a growing trend among organisations to address climate change and enhance sustainability within their operations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Stoke Therapeutics, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
